Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors
Lung cancer is a major cause of cancer-related deaths. Alectinib is the first line of treatment
for patients with ALK-positive lung cancer, but the survival rate beyond 2–3 years is low. Co …
for patients with ALK-positive lung cancer, but the survival rate beyond 2–3 years is low. Co …